Core Laboratories (NYSE:CLB) Updates Q1 2026 Earnings Guidance

by · The Cerbat Gem

Core Laboratories (NYSE:CLB – Get Free Report) updated its first quarter 2026 earnings guidance on Wednesday. The company provided earnings per share guidance of 0.110-0.150 for the period, compared to the consensus earnings per share estimate of 0.160. The company issued revenue guidance of $124.0 million-$130.0 million, compared to the consensus revenue estimate of $129.5 million.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Core Laboratories in a research report on Monday, December 29th. Four investment analysts have rated the stock with a Hold rating, According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $12.50.

Read Our Latest Research Report on CLB

Core Laboratories Stock Performance

Shares of NYSE:CLB traded down $0.74 during midday trading on Thursday, reaching $18.87. 551,752 shares of the company traded hands, compared to its average volume of 356,491. The firm’s fifty day moving average price is $17.62 and its two-hundred day moving average price is $14.41. The firm has a market capitalization of $878.59 million, a price-to-earnings ratio of 28.20, a price-to-earnings-growth ratio of 17.14 and a beta of 1.09. The company has a quick ratio of 1.76, a current ratio of 2.37 and a debt-to-equity ratio of 0.41. Core Laboratories has a 12 month low of $9.72 and a 12 month high of $20.36.

Core Laboratories (NYSE:CLB – Get Free Report) last issued its earnings results on Wednesday, February 4th. The oil and gas company reported $0.21 EPS for the quarter, topping the consensus estimate of $0.20 by $0.01. Core Laboratories had a return on equity of 12.85% and a net margin of 6.21%.The business had revenue of $138.26 million during the quarter, compared to the consensus estimate of $130.40 million. During the same quarter last year, the company earned $0.22 EPS. The firm’s revenue was up 7.0% compared to the same quarter last year. Core Laboratories has set its Q1 2026 guidance at 0.110-0.150 EPS. On average, equities analysts expect that Core Laboratories will post 0.96 earnings per share for the current year.

Core Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 9th. Shareholders of record on Monday, February 16th will be paid a $0.01 dividend. The ex-dividend date is Friday, February 13th. This represents a $0.04 annualized dividend and a yield of 0.2%. Core Laboratories’s dividend payout ratio is currently 5.97%.

Core Laboratories News Roundup

Here are the key news stories impacting Core Laboratories this week:

  • Positive Sentiment: Q4 results: Revenue and EPS beat consensus — Core Labs reported $138.25–138.3M in Q4 revenue (≈+7% YoY) and reported EPS of $0.21, topping the Zacks/consensus estimate by $0.01; gross and operating profits improved year‑over‑year. Core Laboratories (CLB) Beats Q4 Earnings and Revenue Estimates
  • Neutral Sentiment: Dividend declared — CLB announced a $0.01 quarterly dividend (ex‑div Feb 13, record Feb 16, pay Mar 9), a very small yield (~0.2%) that is unlikely to materially move investor sentiment. (Company release)
  • Negative Sentiment: Q1 2026 guidance below consensus — Management gave Q1 EPS guidance of $0.110–0.150 (Street ≈ $0.160) and revenue guidance of $124M–$130M (Street ≈ $129.5M), signaling a softer near‑term outlook that likely pressured the stock. Core Laboratories posts Q4 2025 results and dividend
  • Negative Sentiment: Weaker operating cash flow and mixed profitability metrics — third‑party coverage highlighted a sharp drop in operating cash flow (reported ~‑60% YoY) despite higher revenue and gross profit, raising near‑term free‑cash‑flow concerns. This contributed to downward pressure on the stock. Core Laboratories Inc. (CLB) Stock Falls on Q4 2025 Earnings

Institutional Investors Weigh In On Core Laboratories

Institutional investors and hedge funds have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Core Laboratories by 4.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 27,893 shares of the oil and gas company’s stock valued at $418,000 after buying an additional 1,170 shares in the last quarter. American Century Companies Inc. raised its stake in shares of Core Laboratories by 14.3% during the second quarter. American Century Companies Inc. now owns 133,033 shares of the oil and gas company’s stock worth $1,533,000 after acquiring an additional 16,677 shares in the last quarter. Quantbot Technologies LP lifted its holdings in shares of Core Laboratories by 343.7% in the 2nd quarter. Quantbot Technologies LP now owns 17,520 shares of the oil and gas company’s stock worth $202,000 after acquiring an additional 13,571 shares during the last quarter. Sei Investments Co. purchased a new stake in shares of Core Laboratories in the 2nd quarter valued at $231,000. Finally, The Manufacturers Life Insurance Company grew its holdings in shares of Core Laboratories by 6.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 17,932 shares of the oil and gas company’s stock valued at $207,000 after purchasing an additional 1,040 shares during the last quarter. Hedge funds and other institutional investors own 97.81% of the company’s stock.

Core Laboratories Company Profile

(Get Free Report)

Core Laboratories N.V. is a global provider of proprietary and patented reservoir description and production enhancement services to the oil and gas industry. The company applies specialized expertise in core and fluid analysis, advanced petrophysical interpretation, and reservoir engineering to optimize hydrocarbon recovery. By integrating laboratory testing with field services and digital analytics, Core Laboratories delivers insights that help operators maximize production and extend the life of their assets.

The company’s portfolio spans two primary service lines: reservoir description and production enhancement.

Recommended Stories